Blueprint Medicines Corp. (BPMC): שולי רווח תפעולי

סמלים רשמיים של חברת Blueprint Medicines Corp. (BPMC)

A global alliance with Roche and Genentech is accelerating the market launch of therapies for rare blood pathologies for Blueprint Medicines (BPMC). The operating profit margin reflects the impact of this partnership, with the value stabilizing at -31.00. Business efficiency is bolstered by robotic bio-screening systems and the creation of a closed scientific circuit of precision kinase inhibitors, which minimizes the fundamental risks for Blueprint Medicines (BPMC).

BPMC - שיעור רווח תפעולי Blueprint Medicines בטווח 04.07.2022 - 02.08.2025

Blueprint Medicines Corp. - פילוחים אנליטיים ומדדי מפתח (BPMC)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח פונדמנטלי של החברה:BPMC, Blueprint Medicines Corp.
מוצרים מוגמרים של Blueprint Medicines Corporation

For the biotech company Blueprint Medicines (BPMC), which maintains a minimal environmental footprint and a focus on laboratory safety, controlling operating expenses has become a key efficiency driver. The current operating margin reflects the portion of revenue remaining after covering primary expenses before interest and taxes, allowing investors to assess the fundamental stability of the business model and the justification of the company's market valuation.